Martin Kaiser Profile picture
May 13, 2022 5 tweets 3 min read Read on X
Just as there is notably wider interest in chr1q abnormalities in myeloma now than when our data was published: here again a link to the excellent work chr1q copy number evolution and its clinical impact from James Croft on #UKMRA #MyelomaXI trial nature.com/articles/s4137…
By investigating new copy number aberrations detected at relapse in 179 matched presentation-relapse tumours from #MyelomaXI, James discovered newly detected 1q aberrations to be most frequent, followed by del13q and del17p. As previous tweet shows, with equal adverse OS.
DigitalMLPA, the method used to detect these, is sensitive and allowed to look up how many of new 1q relapses had sub-clonal gain(1q) at presentation: answer is some, but not the majority.
There were other interesting findings, such as that amp1q only in the minority of cases occurred in isolation - most amp1 tumours also carried a high-risk translocation or another high-risk CNA.
Newly detectable del1p was also associated with inferior OS, as was newly detectable MYC gain. With increasing choice of relapse treatments, repeat genetic profiling should ideally become more widely accessible to myeloma patients (currently not the case in many countries). /Fin

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Martin Kaiser

Martin Kaiser Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MyMKaiser

Dec 27, 2022
We had an early Christmas with our team's latest work out in @BloodJournal. We investigated the benefit patients derive from Lenalidomide Maintenance in context of tumour genetics. ashpublications.org/blood/article-…
Our aim was to interrogate clinically accessible markers that can support care discussions. The Len Maintenance registration trials included limited genetics. We investigated 556 patients with extended genetics randomized post ASCT to Len Maint or Observation in #MyelomaXI
Extended genetics included all HRCA del(1p), gain(1q) & t(14;16)/t(14;20) + standard t(4;14) and del(17p), demonstrating the challenge of reporting on individual genetic markers in #myeloma – e.g. >50% of ‘t(4;14) patients’ also carried at least one other HRCA (=double hit).
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(